Background: To date it is proved that Alzheimer's disease (AD) is characterized by a multifactorial etiology which comprises mitochondrial dysfunction, energy depletion, inflammation, and oxidative stress associated with glutathione depletion. All these factors are known to be impacted by beta amyloid protein (Aβ), which is responsible for the activation of amyloidogenic cascade. In the present work a rat intracerebroventricular Aβ(1-40) infusion model of early AD was employed to investigate the effects of Ibuprofen-Glutathione (IBU-GSH) conjugate on morphological modifications, Aβ plaque formation, apoptosis, learning, and memory performance.
Introduction
Alzheimer's disease (AD) is the most common form of dementia, associated with cardinal symptoms such as progressive memory loss due to the degeneration of neurons and synapses in the cerebral cortex and subcortical regions of the brain [1, 2] . Neuropathologically, AD is characterized by the extracellular deposition of β-amyloid (Aβ) peptides, neurofibrillary tangle formation, chronic inflammatory response and oxidative damage [3] . The pathogenic cascade that leads to neurodegeneration in AD brain results in the production of Aβ-associated free radicals, oxidative stress, and alterations to Glutathione (GSH) metabolism [4] . In this context, studies by Gu et al. [5] reported that GSH levels are depressed in AD cingulated cortex and AD substantia innominata, while Liu et al. [6] found these reduced levels only in red blood cells of male AD patients. It has been observed that GSH protects cultured neurons against oxidative damage resulting from β-peptide and 4-hydroxynonenal (HNE), a lipid peroxidation product that is increased in AD [7] . A significant decrease in Cu and significant increases in Zn and Fe were found in AD hippocampus and amygdala, while Cu, Fe, and Zn are elevated in senile plaques of AD. These metal ions can catalyze free radical reactions and contribute to oxidative damage observed in AD brain [8] . GSH protects these areas through formation of metal complexes via non enzymatic reactions and may also be beneficial for normalizing the adverse effects of iron accumulation in the aging brain [9] .
Moreover, Aβ deposition is also involved in the initiation of the inflammatory damage, which consequently led to neuronal cell apoptosis evoking gene expression of several inflammatory cytokines such as monocyte chemoattractant protein-1, interleukin (IL)-1β, and IL-6 in cultured human brain endothelial cells [10] . Regardless of the exact mechanism, the cytotoxicity of Aβ has been definitively linked to its aggregation and to the disruption of cell membranes by A [11] . The dependence on gangliosides in the membrane disruption process corroborates previous results in that they clearly influence an alternative pathway for Aβ aggregation. Aβ polymerization in the presence of gangliosides generates structurally distinct aggregates; however, specific morphological features of these aggregates have yet to be determined [12] . Structural models have been constructed for the final amyloid product of aggregation. Although individual studies have probed the conformational preferences of the Aβ (1-40) monomer, the high-resolution structure of Aβ at 15°C at pH 7.3 with 50 mM NaCl has been solved by Vivekanandan et al. [13] suggesting that in this condition Aβ (1-40)adopts a folded conformation notably different from that seen in most previous NMR experiments. Moreover, molecular dynamics simulations showed that the Aβ (1-40) monomer transiently binds to the Aβ (1-40) oligomer by non-native contacts with the side chains before being incorporated into the fiber through native contacts with the peptide backbone [14] . Combining 19F NMR with other spectroscopic techniques, more detailed information on the secondary structure of intermediates involved in amyloid formation could be obtained [15] .
Agents with anti-inflammatory activities might potentially protect neurons against Aβ-induced neurotoxicity and enhance neuronal cell survival. For many years ibuprofen (IBU) has been considered the best non-steroidal anti-inflammatory drug (NSAID) for the treatment of AD, as it specifically reduces pro-amyloidogenic α1-antichymotrypsin mediated by reduction of interleukin-1β [16] ; furthermore, it seems to prevent the development of the disease, as demonstrated by both epidemiological and clinical studies [17, 18] . Data from in vivo experiments demonstrated that IBU impacts amyloidogenesis and chronic inflammation [19] , even if not all studies found an apparent protective effect of non-selective NSAIDs [20] .
The rational structure-based design strategy can generate small molecules that can be target and modulate the multiple AD pathological factors [21] . Oxidative stress, metal ion dyshomeostasis, neuroinflammation, and Aβ aggregation that are strictly connected with the onset of AD, constitute a relevant therapeutical targets to address multifunctional ligand [21] [22] [23] [24] [25] . In our previous study, to improve the performance of the therapeutic treatment of AD, IBU and GSH have been covalently joined via an amide bond to enhance their brain availability and administered in a chronic treatment to Aβ(1-40)-infused AD rat brain model [26] [27] [28] . Results emerging from that study indicated that IBU-GSH possessed good in vitro physicochemical and antioxidant properties; it exhibited good stability toward enzymatic activity in human plasma and, like GSH, displayed in vitro free radical scavenging activity in a time and concentrationdependent manner [26] . Such compound might allow targeted delivery of IBU and GSH directly to neurons.
The aim of this work was to go deeper in the investigation of GSH-IBU on morphological and ultrastructural modifications, Aβ plaque number, inflammatory inducible Nitric Oxide Synthase (iNOS) protein and caspase-3 protein expression, and apoptosis rate occurrence in parallel to learning and memory performance.
Materials and Methods

Animals
Male Wistar rats (n=24) (Harlan, UD, Italy), weighing 200-225 g at the beginning of the experiments, were used. The animals were individually housed in a single room on a 12 h light/dark cycle (lights off at 7:00 AM.) at constant temperature (20-22°C) and humidity (45-55%). Rats were offered food pellets (4RF; Mucedola, Settimo Milanese, Italy) and tap water ad libitum and were handled once a day for 5 min during the first week after arrival. Each animal was weighted weekly throughout the experimental period. All procedures were conducted in adherence to the European Community Council Directive for Care and Use of Laboratory Animals.
Drug preparation
IBU-GSH conjugate was synthesized and fully characterized as previously reported by us [26] . Aβ (1-40) was prepared as previously described [27, 29] to achieve a final concentration of 0.023 nmol/μL through progressive dilutions starting from 1 mM . IBU-GSH conjugate was solubilised in sterile saline solution containing 2% (v/v) DMSO and daily administered subcutaneously (s.c.) for 28 days at a dose of 10 mg/kg in a volume of 250 μL/kg. A vehicle solution, prepared with sterile saline solution containing 2% (v/v) DMSO, was also administered subcutaneously for 28 days at a dose volume of 250 μL/kg.
Animals treatment
After anaesthesia with 10 mg/kg of a mixture of zolazepam and tiletamine (Zoletil 100, Italmed, Italy) by intraperitoneal injection, a stainless steel cannula was implanted in the lateral cerebroventricle of the animal using a stereotaxic instrument: anteroposterior, 1.0; lateral, 1. in the osmotic pump was 23 µM [30] . The animals were divided in three groups (n=8 rats): a control group, an Aβ-treated group, and an Aβ+IBU-GSH conjugate-treated group. The first group continuously received the vehicle infused into the lateral ventricle by osmotic pump for 28 days; contemporaneously, vehicle was injected daily s.c. The second group constantly received Aβ (1-40) infused into the lateral ventricle for 28 days; vehicle was injected daily s.c. The third group continuously received Aβ (1-40) infused into the lateral ventricle for 28 days and simultaneously IBU-GSH conjugate was injected daily s.c.
Water maze test
To assess the effect on the impairment of learning abilities in Aβ-infused AD rat model, rats were trained in a standard Morris water maze task one month after treatment with IBU-GSH [26] . Training consisted of four trials per day for five consecutive days and the intertrial interval was 30 s. Each trial was stopped when the rat reached the hidden platform or when 90 s elapsed.
On day 6 (i.e., 24 hrs following the last day of training) a probe trial was performed in which the platform was removed from the pool to measure the time spent in the target quadrant where the platform was located during the training. This assessment provided an evaluation of strength and accuracy of the memory of the previous platform location. On day 12 (i.e., 6 days post-training) a second probe trial was performed in which the platform was removed. Both probe trials provided an estimate of the long-term spatial memory consolidation. The time elapsed in the probe test was 60 s.
Samples withdrawal
Rats were killed by CO 2 , brains were rapidly removed, then divided in the two hemispheres, and each half randomly processed for light and electron microscopy. The whole hemispheres were (average size: 2 cm height, 0.5 cm width and 0.5 cm depth) fixed in 10% phosphatebuffered formalin at pH 7.0 for 48 h and dehydrated through ascending concentrations of alcohol and xylene, and then paraffin embedded. For electron microscopy rat cortex was isolated, immediately put into fixative solution (2.5% glutaraldehyde in 0.1 M phosphate buffer at pH 7.6), sectioned (average size: 0.3 cm width, 0.3 cm height, and 0.3 cm depth) and maintained into fixative solution for 4 hrs at 4°C. After washing in the same buffer, samples were post-fixed in 1% OsO 4 in phosphate buffer for 1 hrs at 4 °C, acetone dehydrated and Epon embedded followed by polymerization for 3 days at 60°C.
Transmission Electron Microscopy
Ultra-thin cortex sections (100 nm) were cut and mounted on 300 mesh nickel grids. Uranyl acetate and lead citrate counterstained grids were observed using transmission electron microscopy (Zeiss 109). Cerebral cortex semi-thin sections (1 μm) were stained with 1% toluidine blue and observed at light microscopy.
Morphological and immunohistochemical analyses
Samples were then defatted with xylene and alcohol with progressively lower concentrations, and 5μm thick frontal section were processed for immunohistochemical and TUNEL analyses. DNA strand breaks, yielded during apoptosis, can be identified by labeling free 3′-OH termini with modified nucleotides in an enzymatic reaction. All steps were carried out with FragEL DNA fragmentation Detection Kit according to the manufacturer's instructions (Calbiochem Merck, Cambridge, MA, USA). After two rinses in PBS, slides were dehydrated, mounted by using a permanent media, and analyzed by light microscope (Leica Cambridge Ltd, Cambridge, UK). Five slides from each sample were assessed; apoptotic cells count was performed on ten fields per slide. Negative control was performed by omitting the incubation in the presence of the enzymatic mixture, positive control (not shown) was performed by treating one slide with DNAse I.
In order to detect Aβ (1-40), iNOS, and cleaved caspase-3 proteins, immunohistochemistry was performed on 5 μm thick sections by means of Ultravision LP Detection System HRP Polymer & DAB Plus Chromogen (Lab Vision Thermo, CA, USA). Slides were first covered with 10 mM sodium citrate buffer at pH 6.0, heated at 95°C for 5 minutes to unmask antigens, and then incubated in the presence of rabbit anti-cleaved caspase-3 monoclonal antibody (Cell Signalling Technology Inc, MA, USA), rabbit anti-iNOS polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz CA) and mouse anti-Aβ(1-40) monoclonal antibody (Alpha Diagnostic International, TX, USA). Negative controls were performed by omitting primary antibodies, according to the manufacturer's instructions. Samples were then observed by means of light microscopy Leica DM 4000 (Leica Cambridge Ltd, Cambridge, UK) equipped with a Leica DFC 320 camera (Leica Cambridge Ltd, Cambridge, UK) for computerized images.
Computerized Morphometry measurements and Image Analysis
To evaluate Aβ expression, computerized images derived from immunohistochemical stained sections were analyzed by QWin Plus 3.5 software (Leica Cambridge Ltd, Cambridge, UK). Image analysis of Aβ expression was performed through quantification of thresholded area for immunohistochemical brown-colored Aβ on ten fields for each slide (five) per each of sample (three), chosen through systematic and uniformly random sampling of the fields of vision through a predefined XY step, at 40 magnification by Leica Qwin Plus 3.5 Software. Image analysis of cleaved caspase-3 and iNOS expression was performed through quantification of positive cells out of total of 100 cells, at 40 magnification by Leica Qwin Plus 3.5 Software. Five slides per sample were examined. QWin Plus 3.5 assessments were logged to Microsoft Excel and processed for Standard Deviations and Histograms.
Statistics
Statistical analysis was performed using the analysis of variance (ANOVA) and results expressed as mean ± SD. Appropriate post-hoc analysis was carried out using the Newman-Keuls test. Values of p <0.05 were considered statistically significant.
Results
In this paper it was investigated whether IBU-GSH conjugate ( Figure 1 ) could improve learning and memory impairment in an infused Aβ (1-40) rat model. It was found that the time spent to reach the platform by Aβ+IBU-GSH treated group was lower at the second and third day of training respect to the time spent by the Aβ treated group. However, since the values were not statistically different (P=0.05), it was assumed that both groups, treated with Aβ and Aβ +IBU-GSH, respectively, show the same performance in learning (Figure 2 ). Concerning the long-term memory consolidation, all groups at the probe tests 24 hrs (day 6) after training do not show any differences. Furthermore, one week after training (day 12), the performance of Aβ+IBU-GSH treated group is improved, compared to Aβ-treated group (p < 0.05), as shown in Table 1 . Thus, IBU-GSH treatment seems to be effective in slowing down the Aβ plaques deposition by preserving long-term memory in treated rats. Another explanation, could be that the animals treated with IBU+GSH conjugate show less extinction than the other groups.
Day of probe trial
Time spent in the target quadrant (s) To verify AD induction after Aβ (1-40) infusion, cortex sections were processed for Aβ immunohistochemical analysis finding a lower number of Aβ plaques and protein expression in Aβ-infused cerebral cortex of rats treated with IBU-GSH respect to the Aβ-infused ones ( Figure 3A and 3B) . Also morphological modifications were evaluated through a preliminary analysis performed at light microscope by means of toluidine blue stained semithin sections. This analysis discloses the control sample showing six well-organized and conserved cells layers, connected by oligodendrocytes. On the other hand, Aβ-infused rat cerebral cortex shows amyloid plaques, disorganized cells layers with collapsed pyramidal pyknotic cellslikely apoptotic cells and a lower number of oligodendrocytes -while IBU-GSH treated cerebral cortex show a lower number of pyknotic cells along with reorganized neurons ( Figure 4A ). These findings led us to better investigate the morphological situation focusing attention on mitochondria through an electron microscopy analysis, which reveals a large number of well-preserved mitochondria in control sample, fragmented or swollen mitochondria and Golgi apparatus in Aβ-infused cortex, while mitochondria with normal structure and regular cristae are found in IBU-GSH treated cerebral cortex ( Figure  4B ). As the cellular suffering evidenced by the morphological analysis could be due to an inflammatory state, the expression of iNOS-a key factor in the inflammation onset-was evaluated through immunohistochemical analysis. iNOS level appears significantly higher in Aβ-infused cortex respect to IBU-GSH treated cerebral cortex ( Figure 5A and 5B).
Finally, the apoptotic event occurrence supposed after the morphological evaluation, was investigated through both TUNEL analysis and pro-apoptotic caspase-3 expression, disclosing a significantly lower percentage of apoptotic nuclei in Aβ-infused rat cerebral cortex treated with IBU-GSH compared to the Aβ-infused one ( Figure 6A and 6B) . The reduction of apoptotic cell percentage is matched to a weak pro-apoptotic caspase-3 level in the same experimental conditions (Figure 7A and 7B). 
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Discussion
This report describes the in vivo effects exerted by IBU-GSH conjugate on morphological modifications, Aβ plaque formation, iNOS protein expression, and apoptosis rate occurrence in parallel to learning and memory performance in Aβ(1-40)-infused rat cerebral cortex, which represents a model of AD. Although the etiology of AD has not been exhaustively elucidated yet, mitochondrial dysfunction, metal-ion dysregulation, and oxidative stress have been linked to the progressive neurological decline associated with this neurodegenerative disorder [3, [31] [32] [33] . In oxidative stress conditions, GSH is able to detoxify various oxidants by directly scavenging free radicals and acting as a coenzyme in GSH-peroxidase catalysed reactions and/or chelating agent [6, 23, 34, 35] . Moreover, a recent renewed interest in non-steroidal anti-inflammatory drugs for AD treatment stems from findings suggesting that some NSAIDs (e.g. Ibuprofen, Flurbiprofen) might influence other pathogenic features of AD such as oxidative damage [18, 36] . In this study the potential synergic antioxidant and antiinflammatory properties of IBU-GSH conjugate [26] in rat brains infused with Aβ (1-40), as a model of AD, was investigated [37] . The animals developed Aβ amyloid plaques and spatial memory deficits in a radial maze, as already described [27] . The Aβ (1-40) was chosen for its higher ability to form amyloid fibrils in rats, and its neurodegenerative effect is more pronounced than Aβ (1-42), as evidenced within the CA1 subfield of the hippocampus [38] . Furthermore, Aβ (1-40) is more soluble than Aβ (1-42): in fact, there is less likelihood that it precipitates in the osmotic pumps and/or in the tube connecting the pump to the ventricle. As previously reported [26] , the free radical scavenging activity of IBU-GSH conjugate was evaluated evidencing a dose-dependent radical scavenging activity of the conjugate respect to IBU alone. In particular, neuronal cells and blood vessels organization results modified in AD rat brain; mitochondria appear swollen and their number reduced, along with a significant increase in their size, maybe inducing an aspecific release of mitochondrial matrix components, including Cytochrome c and apoptosis inducing factor 1 (Apaf-1), which can activate a cascade of changes which lead to apoptotic cell death in AD [28, 39] . Upon IBU-GSH conjugate treatment, neuronal cells appear reorganized and mitochondria show restoration of their normal structure and number along with a successful spatial long-term consolidation or longer time of extinction given 6 days after training (day 12) in a Morris water maze task. This treatment also reverses the Aβ-induced iNOS over-expression, strongly related to the spatial memory impairment, as already reported by Huang et al. [40] . The recruitment of healthy elongated mitochondria, upon antioxidant, anti-inflammatory, and neuroprotective IBU-GSH combined treatment, could be coupled to nerve terminals to supply ATP allowing a better function [41] . These results seem to be paralleled by the inhibition of the apoptotic route driven by caspase-3, due to IBU-GSH combined treatment even though, as suggested by Lamkanfi and Kanneganti [42] , a role was also assigned to caspase-7 in the occurrence of the apoptotic event. In alignment with other reports [43, 44] , and together with other major cellular changes-such as Aβ and amyloid cascade events, synaptic pathology, neuronal loss, and inflammatory responsesmitochondria involvement in the occurrence of AD and neuroprotective and anti-apoptotic functions of IBU-GSH conjugate are here further supported.
Compared to other drugs intended for AD therapy, GSH-IBU conjugate appears to be particularly promising because it acts as neuroprotective and anti-apoptotic agent causing a dramatic reduction in oxidative damage and amyloid deposition in a rat model of AD.
Although basic biophysical studies would be necessary to elucidate how IBU-GSH conjugate may interfere with Aβ aggregation process, taken together, these results are of significance for prospective therapeutic application of our conjugate in neuropathological events associated with free radical damage, mitochondrial dysfunction, and apoptosis.
